Boston Scientific vs Medline
BSX and MDLN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BSX and MDLN compare
Boston Scientific is the larger company, worth 1.2 times as much as Medline ($64.3B against $51.9B).
Boston Scientific scores higher on the StockData Score (14 against 2 for Medline), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BSX | MDLN |
|---|---|---|
| Size and price | ||
| Market cap | $64.3B | $51.9B |
| Share price | $44.34 | $39.47 |
| Change, 1 year | −57.4% | – |
| Change, 5 years | 8.1% | – |
| Beta (5Y) | 0.78 | – |
| Employees | 59K | 45K |
| StockData Score | ||
| Total score | 14 (better) | 2 |
| Valuation score | 6 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 18.8× | – |
| P/S | 3.0× | 1.7× (better) |
| P/B | 2.5× (better) | 4.4× |
| EV/EBITDA | 14.1× (better) | 24.7× |
| P/FCF | 19.3× (better) | 27.4× |
| PEG | 0.30 | – |
| FCF yield | 5.2% (better) | 3.7% |
| Fair value | $89.83 | $23.81 |
| Margin of safety | 50.6% (better) | −65.8% |
| Growth | ||
| Revenue growth (TTM) | 8.9% | – |
| Revenue growth, 5Y average | 15.2% | – |
| EPS growth (TTM) | 26.2% | – |
| Profitability | ||
| Gross margin | 69.1% (better) | 25.7% |
| Operating margin | 18.7% (better) | 5.7% |
| FCF margin | 15.8% (better) | 6.2% |
| Return on invested capital | 10.6% (better) | 6.6% |
| Financial health | ||
| Debt / equity | 0.47 (better) | 1.07 |
| Net debt / EBITDA | 2.11 (better) | 3.24 |
| Interest coverage | 10.5× (better) | 2.5× |
| Current ratio | 1.36 | 4.04 (better) |
| Altman Z-score | 3.03 (better) | 2.70 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.1% | 57.1% |
| Held by insiders | 0.20% | 81.6% |
| Insider net buying, 12 months | −$6.8M (better) | −$14.3B |
| Superinvestors holding | 1 | 4 (better) |
| Short interest, % of float | 2.4% | 15.7% |
Go deeper
- BSX stock overview
- BSX income statement
- BSX valuation and score
- MDLN stock overview
- MDLN income statement
- MDLN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.